Product How it works Pricing Blog FAQ About Contact
Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) revenue

Entrada Therapeutics reported revenue of $25.4m for fiscal 2025, 87.9% less than in fiscal 2024 ($210.8m). Since fiscal 2023 its revenue has fallen by 80.3%, an average decline of 55.6% a year.

Entrada Therapeutics's best year of the last 3 was fiscal 2024. The biggest drop was in fiscal 2025, −87.9%.

Revenue, in millions of US dollars129.02023210.8202425.42025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$25.4m−87.9%−$157.9m−621.1%
2024$210.8m+63.4%$47.0m22.3%
2023$129.0m—−$3.2m−2.5%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Entrada Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Entrada Therapeutics ranks 352nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Entrada Therapeutics, −87.9%.

RankCompanyRevenueRevenue growth
350thVerastem$30.9m209.1%
351stFoghorn Therapeutics$30.9m36.8%
352ndEntrada Therapeutics$25.4m−87.9%
353rdAlumis$24.1m—
354thAlector$21.0m−79.1%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Entrada Therapeutics

How much revenue did Entrada Therapeutics make in fiscal 2025?
Entrada Therapeutics reported revenue of $25.4m for fiscal 2025, compared with $210.8m in fiscal 2024.
How much has the revenue of Entrada Therapeutics fallen?
Between fiscal 2023 and fiscal 2025 it went from $129.0m to $25.4m: 80.3% less, an average decline of 55.6% a year.
What was the best year for revenue at Entrada Therapeutics?
Of its last 3 fiscal years, fiscal 2024, with $210.8m.
Where does Entrada Therapeutics rank in its sector by revenue?
It ranks 352nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Entrada Therapeutics come from?
From the annual report (Form 10-K) that Entrada Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Entrada Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Entrada Therapeutics: the Entrada Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.